<code id='1B92B2C2C2'></code><style id='1B92B2C2C2'></style>
    • <acronym id='1B92B2C2C2'></acronym>
      <center id='1B92B2C2C2'><center id='1B92B2C2C2'><tfoot id='1B92B2C2C2'></tfoot></center><abbr id='1B92B2C2C2'><dir id='1B92B2C2C2'><tfoot id='1B92B2C2C2'></tfoot><noframes id='1B92B2C2C2'>

    • <optgroup id='1B92B2C2C2'><strike id='1B92B2C2C2'><sup id='1B92B2C2C2'></sup></strike><code id='1B92B2C2C2'></code></optgroup>
        1. <b id='1B92B2C2C2'><label id='1B92B2C2C2'><select id='1B92B2C2C2'><dt id='1B92B2C2C2'><span id='1B92B2C2C2'></span></dt></select></label></b><u id='1B92B2C2C2'></u>
          <i id='1B92B2C2C2'><strike id='1B92B2C2C2'><tt id='1B92B2C2C2'><pre id='1B92B2C2C2'></pre></tt></strike></i>

          leisure time

          leisure time

          author:Wikipedia    Page View:7
          Cholesterol
          APStock

          Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

          Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed  reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

          advertisement

          The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Listen: PBM conflicts, RSV vaccines, & the future of flu season
          Listen: PBM conflicts, RSV vaccines, & the future of flu season

          SammyKimballforSTATWho’swatchingthedrugpricewatchmen?AreRSVvaccinestooexpensive?Andisitfinallytimefo

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          FDA gives detailed accounting of AI

          AdobeTheFoodandDrugAdministrationonThursdayreleasedanewaccountingofartificialintelligencetoolscleare